Table 1.

Characteristics of the RA cohort.

CharacteristicMTX MonotherapyLEF MonotherapyMTX + LEFNeither*
N (%)1552 (52.2)217 (7.3)415 (13.9)791 (26.6)
Sex, %
  Female72.775.972.776.7
  Male27.324.127.323.3
Mean age, yrs (SD)63.0 (13.8)63.0 (12.8)60.0 (12.8)62.0 (13.7)
DAS28 available, n (%)892 (57)100 (46)228 (54)235 (29)
DAS28, mean (SD)2.9 (1.2)3.2 (1.2)3.3 (1.4)2.8 (1.3)
Other medications
  Prednisone, %34.037.339.322.9
  Prednisone daily dose, mean (SD)6.8 (6.2)5.4 (2.6)6.5 (4.0)7.4 (5.9)
  NSAID19.414.719.515.5
Comorbidities, %
  Viral hepatitis0.10.50.00.3
  Other liver disease0.53.70.51.1
  Diabetes4.64.64.14.4
  Steatohepatitis0.20.90.00.3
  Blood disorders2.31.82.94.3
  Infectious diseases0.80.01.91.0
  • * Nonbiologic disease-modifying antirheumatic drug other than MTX and LEF. MTX: methotrexate; LEF: leflunomide; DAS: Disease Activity Score; NSAID: nonsteroidal antiinflammatory drug.